Alkermes (ALKS) vs SIGA Technologies (SIGA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Alkermes (ALKS) has outperformed SIGA Technologies (SIGA) over the past year, gaining 29.4% versus a loss of 61.2%. Over five years, ALKS leads with a +28.2% price change compared with -53.9% for SIGA. Alkermes is the larger company by market cap ($6.81 billion vs $235.7 million), about 28.9 times the size.
On valuation, SIGA Technologies trades at a lower forward P/E (3.0x vs 22.5x for Alkermes).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALKS | SIGA |
|---|---|---|
| Share price | $40.61 | $3.28 |
| Market cap | $6.81B | $235.67M |
| 1-day change | +1.25% | 0.00% |
| YTD return | +45.14% | -46.32% |
| 1-year return | +29.41% | -61.18% |
| 5-year return | +28.23% | -53.87% |
| P/E ratio (TTM) | 106.87 | — |
| Forward P/E | 22.46 | 3.04 |
| EPS (TTM) | $0.38 | $-0.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.48B | — |
| Revenue growth (YoY) | -5.25% | — |
| Net income (latest FY) | $241.66M | — |
| Gross margin | 86.69% | — |
| Operating margin | 17.21% | — |
| Net margin | 16.37% | — |
| 52-week high | $55.67 | $8.55 |
| 52-week low | $27.00 | $2.83 |
| Distance from 52-week high | -27.05% | -61.64% |
| Analyst consensus | buy | none |
| Avg. price target upside | +38.59% | — |
| Average volume | 1.86M | 724.21K |
| Shares outstanding | 167.76M | 71.85M |
| Employees | 2,050 | 49 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Alkermes is about 28.9 times larger than SIGA Technologies by market value ($6.81B vs $235.67M).
- ALKS has outperformed SIGA by 90.6 percentage points over the past year.
About Alkermes
ALKS stock →Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 2,050 employees
About SIGA Technologies
SIGA stock →SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security market in the United States. The company's lead product is TPOXX, an antiviral drug for the treatment of human smallpox disease caused by variola virus.
Health Care · Biotechnology: Pharmaceutical Preparations · 49 employees
ALKS vs SIGA FAQ
Which is bigger, Alkermes or SIGA Technologies?
Alkermes (ALKS) is larger, with a market capitalization of $6.81B compared with $235.67M for SIGA Technologies (SIGA).
Which stock has performed better over the past year, ALKS or SIGA?
ALKS returned +29.41% over the past 12 months, compared with -61.18% for SIGA (price return, excluding dividends). Past performance does not predict future results.
Are Alkermes and SIGA Technologies in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.